In conclusion, our study highlights the potential prognostic value of PIK3CA mutations, particularly H1047R, for predicting disease recurrence among women with HR+/HER2- early or locally advanced operable breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.